Monday, June 18, 2012
A spate of Phase III data
events over the next two years will give a readout on how correctly the lessons
learned five years ago about cancer immunotherapies targeting T cell responses
have been put into practice. But the next wave of therapies already is testing
and building upon new insights brought about by the success of Yervoy
ipilimumab, the first of the immune checkpoint inhibitors.
Corp.'s Provenge sipuleucel-T, which was approved to treat metastatic
castration-resistant prostate cancer (CRPC) in 2010, proved the longstanding
hypothesis that it is possible to induce a cancer patient's T cells to mount
enough of a response against tumors to produce a measurable clinical effect (see
BioCentury, April 20, 2009).